Melanoma – NCI-07-C-0175
Dr. Steven A. Rosenberg
Principal Investigator
NCI is currently conducting the following trial for patients with melanoma. Click on the trial below for additional details, including a summary of eligibility criteria, treatment plan, and information on how to contact Dr. Rosenberg and his staff directly.
You may also call the Clinical Trials Referral Office at 1-888-NCI-1937 (1-888-624-1937) to inquire about referring a patient to this trial.
Leukapheresis and cell preparation:- Patients undergo leukapheresis to obtain peripheral blood mononuclear cells, which are subsequently cultured in the presence of anti-CD3 (OKT3) and aldesleukin
- Cells are then transduced by exposure to anti-MART-1 F5 T-cell receptor
(TCR) genes and expanded in culture
- Patients receive a preparative regimen of cyclophosphamide IV over 1 hour on Days -7 and -6 and fludarabine phosphate IV over 30 minutes on Days -5 to -1
Why is this trial important?
This trial provides an opportunity for patients to participate in an experimental regimen designed to test a new treatment for patients with cancers that are progressive despite available conventional treatments.
Back to Top
